Safety Profile
Known Safety Concerns
- Warfarin potentiation -- documented drug interaction
- Furanocoumarin-induced photosensitivity
- Hormone-sensitive conditions -- contraindicated
- Contraindicated in pregnancy
Contraindications
- Warfarin potentiation -- documented drug interaction
- Furanocoumarin-induced photosensitivity
Interactions
Information not yet available for this ingredient profile.
Evidence and Scientific Findings
Ingredient Overview
Dong Quai (Angelica sinensis) is widely used in Traditional Chinese Medicine for female reproductive health. Contains furanocoumarins with photosensitizing properties. Possesses anticoagulant properties that potentiate warfarin and other anticoagulants. Contains estrogen-like phytochemicals; contraindicated in hormone-sensitive cancers. Safety in pregnancy not established.
Biological and Chemical Classification
- Scientific Name
- Angelica sinensis
Mechanism of Action
Information not yet available for this ingredient profile.
Clinical Evidence of Effectiveness
Information not yet available for this ingredient profile.
Pharmacokinetics
Information not yet available for this ingredient profile.
Recommended Dosage
Information not yet available for this ingredient profile.
SETI — Scientific Evidence Transparency Index
Executive Summary — Ingredient Assessment
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or RCT)
- Main clinical benefit observed: Botanical
- Evidence consistency: High consistency across studies (100%)
- Warfarin potentiation -- documented drug interaction
- Furanocoumarin-induced photosensitivity
- Hormone-sensitive conditions -- contraindicated
- Contraindicated in pregnancy
The available scientific evidence for Dong Quai indicates notable safety signals that warrant caution. Use should be considered carefully and monitored, particularly in sensitive populations or alongside other medications.
Total SETI Score
High risk| Evidence quality | 10/40 |
| Evidence consistency | 20/20 |
| Safety signals | 0/20 |
| Study recency | 10/10 |
| Evidence transparency | 10/10 |
Evidence Summary
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or systematic review)
- 0 studies identified benefits or no safety concern (GREEN)
- 10 studies reported limited or advisory safety evidence (YELLOW)
Evidence Policy
Only peer-reviewed scientific literature indexed in PubMed or comparable databases is included in this evaluation. Commercial websites, blogs, and marketing materials are excluded. All references include direct traceable links to source documents.
Last updated: 25 მარ 2026, 22:28
Evidence Distribution
-
Observational / other LOW evidence YELLOWSenkyunolide H potentiates bone marrow-derived mesenchymal stem cells therapy for liver cirrhosis by targeting MAEA to enhance ERK-driven HGF secretion. ↗Liang Y et al.. Senkyunolide H potentiates bone marrow-derived mesenchymal stem cells therapy for liver cirrhosis by targeting MAEA to enhance ERK-driven HGF secretion.. Pharmacol Res. 2026. PMID:41830881.PMID 41830881 ↗Journal Pharmacol ResYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41830881/
-
Observational / other LOW evidence YELLOWStructural characterization and in vitro antioxidant and immunomodulatory activities of a water-soluble polysaccharide from Angelica sinensis (ASP-4). ↗Liu Y et al.. Structural characterization and in vitro antioxidant and immunomodulatory activities of a water-soluble polysaccharide from Angelica sinensis (ASP-4).. Int J Biol Macromol. 2026. PMID:41819329.PMID 41819329 ↗Journal Int J Biol MacromolYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41819329/
-
Observational / other LOW evidence YELLOW[Angelica sinensis polysaccharide-chitosan nanosystem synergizes with radiotherapy to enhance anti-tumor immunity and suppress tumor growth]. ↗Wang HJ et al.. [Angelica sinensis polysaccharide-chitosan nanosystem synergizes with radiotherapy to enhance anti-tumor immunity and suppress tumor growth].. Zhongguo Zhong Yao Za Zhi. 2026. PMID:41814818.PMID 41814818 ↗Journal Zhongguo Zhong Yao Za ZhiYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41814818/
-
Observational / other LOW evidence YELLOWFirst Report of Meloidogyne hapla (Nematoda) Parasitizing Angelica sinensis and Panax japonicus in Yunnan Province, China. ↗Gu J et al.. First Report of Meloidogyne hapla (Nematoda) Parasitizing Angelica sinensis and Panax japonicus in Yunnan Province, China.. Plant Dis. 2026. PMID:41814778.PMID 41814778 ↗Journal Plant DisYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41814778/
-
Observational / other LOW evidence YELLOWConcentrated Angelica sinensis pills ameliorate ovarian insufficiency by promoting vascular remodeling via inhibiting CYP1B1/ACSL4-mediated ferroptosis. ↗Ling C et al.. Concentrated Angelica sinensis pills ameliorate ovarian insufficiency by promoting vascular remodeling via inhibiting CYP1B1/ACSL4-mediated ferroptosis.. Phytomedicine. 2026. PMID:41795290.PMID 41795290 ↗Journal PhytomedicineYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41795290/
-
Observational / other LOW evidence YELLOWPorous organic polymers with donor-acceptor architectures as efficient photocatalytic oxidase-like nanozyme for colorimetric detection of organophosphorus pesticides. ↗Li S et al.. Porous organic polymers with donor-acceptor architectures as efficient photocatalytic oxidase-like nanozyme for colorimetric detection of organophosphorus pesticides.. Mikrochim Acta. 2026. PMID:41792480.PMID 41792480 ↗Journal Mikrochim ActaYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41792480/
-
Observational / other LOW evidence YELLOWMechanistic insights into the antidepressant effects of the Angelica sinensis and Ligusticum chuanxiong Herb Pair: Involvement of the PI3K/AKT signaling pathway. ↗Yang TY et al.. Mechanistic insights into the antidepressant effects of the Angelica sinensis and Ligusticum chuanxiong Herb Pair: Involvement of the PI3K/AKT signaling pathway.. J Ethnopharmacol. 2026. PMID:41780614.PMID 41780614 ↗Journal J EthnopharmacolYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41780614/
-
Observational / other LOW evidence YELLOWAngelica sinensis polysaccharide nanoparticles can improve myocardial ischemia-reperfusion injury by inhibiting ferritinophagy via the ATF6/NCOA4 pathway. ↗Chen C et al.. Angelica sinensis polysaccharide nanoparticles can improve myocardial ischemia-reperfusion injury by inhibiting ferritinophagy via the ATF6/NCOA4 pathway.. J Transl Med. 2026. PMID:41749209.PMID 41749209 ↗Journal J Transl MedYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41749209/
-
Observational / other LOW evidence YELLOWHydroalcoholic gel of Angelica sinensis polysaccharides promotes wound healing by suppressing ferroptosis through PI3K/AKT/Nrf2 signaling pathway. ↗Pei J et al.. Hydroalcoholic gel of Angelica sinensis polysaccharides promotes wound healing by suppressing ferroptosis through PI3K/AKT/Nrf2 signaling pathway.. Phytomedicine. 2026. PMID:41724102.PMID 41724102 ↗Journal PhytomedicineYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41724102/
-
Observational / other LOW evidence YELLOWGuaiacol counters renal fibrosis via BMP/ERK/Smad1/5/9 signaling in UUO-induced chronic kidney disease. ↗Kulkarni HV et al.. Guaiacol counters renal fibrosis via BMP/ERK/Smad1/5/9 signaling in UUO-induced chronic kidney disease.. J Nutr Biochem. 2026. PMID:41713711.PMID 41713711 ↗Journal J Nutr BiochemYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41713711/
Score Transparency
0 of 10 approved references (score saturates at 10). More peer-reviewed studies = stronger evidence base.
Method: Q = number of approved references ÷ 10 (capped at 1.0)
Limited — mostly case reports or animal studies
Method: L = mean study-level weight across approved references. Level 1 (meta-analysis / systematic review) = 1.0; Level 2 (RCT) = 0.8; Level 3 (cohort/case-control) = 0.6; Level 4 (case report) = 0.4; Level 5 (animal / in-vitro) = 0.2.
Mixed or neutral — roughly equal benefit and risk signals
Method: D = (sum of risk-scored references − sum of benefit-scored references) ÷ total evidence score, then scaled from [−1, 1] to [0, 1]. 0.0 = pure benefit; 0.5 = neutral; 1.0 = pure risk.
One or more monitoring-level safety signals active
Method: S = 0.5 (neutral baseline) + sum of active signal severity deltas ÷ 10. Severity deltas: Critical = +2.0, High = +1.5, Moderate = +1.0, Low = +0.5. Capped at 1.0.
Final GIRI Score for Dong Quai. Risk level thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
Full methodology & data sources
The GIRI Score is computed entirely from structured data — no editorial scoring or subjective weighting is applied at any step.
- References: Only approved references are counted. Each reference is assigned an evidence level (L1–L5) and a direction (risk / neutral / benefit) by the reference manager or AI classifier.
- Safety Signals: Sourced from regulatory agencies (FDA, EMA, Health Canada, TGA, and others) and pharmacovigilance databases. Only active signals count toward the score.
- Formula version: GIRI Score v3.7.0 — Q × L × D × S × 10.
- Limitations: The score reflects published evidence and recorded signals as of the last update date. It is not a clinical risk assessment and should not replace advice from a qualified healthcare professional.
Risk Level Classification
Based on available regulatory signals and scientific evidence, this ingredient presents a moderate safety concern. Caution is advised, particularly at high doses or in sensitive populations.
0–3.0
3.0–5.5
5.5–7.5
7.5–10
The score pin shows exactly where this ingredient falls on the fixed risk scale.
What drove the Moderate classification for Dong Quai
A score of 5.5 places this ingredient in the Moderate band. Thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
0 approved references.
Limited — mostly case reports or animal studies (Level 4–5).
Neutral or mixed — benefit and risk signals roughly balanced.
No active signals — S component is at neutral baseline (0.5), contributing no extra risk weight.
No major regulatory restrictions or advisories recorded across monitored jurisdictions (FDA, EMA, Health Canada, TGA, and others).
How are the Low / Moderate / High / Critical thresholds defined?
The four risk levels are fixed score bands. A score is assigned to exactly one level based on where it falls:
| Level | Score | Meaning |
|---|---|---|
| LOW | 0.0 – 2.9 | Sparse or predominantly beneficial evidence. No active safety alerts. |
| MODERATE | 3.0 – 5.4 | Mixed signals — some risk alongside benefit. Caution at high doses or in sensitive groups. |
| HIGH | 5.5 – 7.4 | Multiple studies or regulatory alerts documenting adverse effects. Professional oversight recommended. |
| CRITICAL | 7.5 – 10 | Regulatory restrictions in one or more major jurisdictions. Serious documented harm. Avoid without specialist supervision. |
Thresholds are fixed constants (GIRI_Score_Utils::LEVEL_THRESHOLDS). They do not change per ingredient and are never subject to editorial adjustment.